New York S 7431: Establishes a frontotemporal degeneration advisory committee

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S07431 Summary:

BILL NOS07431 

&nbsp

SAME ASSAME AS A08243

&nbsp

SPONSORHINCHEY

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Add Art 20-C §§2020 & 2021, Pub Health L

&nbsp

Establishes a state frontotemporal degeneration advisory committee which shall be charged with recommending to the department long range objectives, goals and priorities, and provide advice on the planning, coordination and development of needed services.

Go to top S07431 Actions:

BILL NOS07431 

&nbsp

04/16/2025REFERRED TO HEALTH

01/07/2026REFERRED TO HEALTH

Go to topS07431 Committee&nbspVotes:

Go to topS07431 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS07431 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 7431

 2025-2026 Regular Sessions

 IN SENATE

 April 16, 2025
 ___________

 Introduced by Sen. HINCHEY -- read twice and ordered printed, and when
 printed to be committed to the Committee on Health

 AN ACT to amend the public health law, in relation to establishing a
 state frontotemporal degeneration advisory committee

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. The public health law is amended by adding a new article
 2 20-C to read as follows:
 3 ARTICLE 20-C
 4 FRONTOTEMPORAL DEGENERATION ADVISORY COMMITTEE
 5 Section 2020. Frontotemporal degeneration advisory committee.
 6 2021. Reports.
 7 § 2020. Frontotemporal degeneration advisory committee. 1. The
 8 department shall, within ninety days of the effective date of this
 9 section, establish a frontotemporal degeneration advisory committee
 10 which shall be charged with recommending to the department long range
 11 objectives, goals and priorities. It shall also provide advice on the
 12 planning, coordination and development of needed services. In making
 13 such recommendations, the committee shall review and consider:
 14 (a) rates of clinical diagnosis of frontotemporal degeneration by
 15 county;
 16 (b) how many records have been included and reported into the depart-
 17 ment's frontotemporal degeneration registry;
 18 (c) demographic information such as patients by age, gender and race;
 19 (d) the number of new diagnoses in the preceding year;
 20 (e) advancements in the treatment of frontotemporal degeneration;
 21 (f) the availability and accessibility of resources for the care of
 22 patients with frontotemporal degeneration and any disparities that may
 23 exist in the regional availability of services;
 24 (g) information related to the cost of care for frontotemporal degen-
 25 eration disorders; and

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD11679-01-5

 S. 7431 2

 1 (h) frequency of and causes of misdiagnosis related to frontotemporal
 2 degeneration disorders.
 3 2. Members of the committee shall be selected by the governor, the
 4 legislature and the commissioner. The governor, the temporary president
 5 of the senate, the speaker of the assembly and the commissioner shall
 6 each select two committee members and the minority leaders of the senate
 7 and the assembly shall each select one committee member. Membership of
 8 the committee shall include:
 9 (i) a neurologist;
 10 (ii) a speech pathologist;
 11 (iii) a primary care provider;
 12 (iv) a physician informaticist;
 13 (v) a patient living with frontotemporal degeneration;
 14 (vi) a caregiver of a patient living with frontotemporal degeneration;
 15 (vii) a public health professional;
 16 (viii) a population health researcher familiar with registries;
 17 (ix) a frontotemporal degeneration researcher;
 18 (x) a member of an organization that raises awareness about and
 19 promotes research for the treatment of frontotemporal degeneration; and
 20 (xi) anyone else the commissioner deems necessary.
 21 3. The members of the committee shall receive no compensation for
 22 their services, but shall be allowed their actual and necessary expenses
 23 incurred in the performance of their duties hereunder, subject to the
 24 approval of the commissioner.
 25 § 2021. Reports. 1. On or before January first, two thousand twenty-
 26 seven, and every year thereafter, the department, in conjunction with
 27 the